help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saukkonen, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saukkonen, J. J.
American Journal of Respiratory and Critical Care Medicine Vol 174. pp. 935-952, (2006)
© 2006 American Thoracic Society
doi: 10.1164/rccm.200510-1666ST


American Thoracic Society Documents

An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy

Jussi J. Saukkonen, David L. Cohn, Robert M. Jasmer, Steven Schenker, John A. Jereb, Charles M. Nolan, Charles A. Peloquin, Fred M. Gordin, David Nunes, Dorothy B. Strader, John Bernardo, Raman Venkataramanan, Timothy R. Sterling on behalf of the ATS Hepatotoxicity of Antituberculosis Therapy Subcommittee

THIS OFFICIAL STATEMENT WAS APPROVED BY THE ATS BOARD OF DIRECTORS, MARCH 2006

Drug-induced liver injury (DILI) is a problem of increasing significance, but has been a long-standing concern in the treatment of tuberculosis (TB) infection. The liver has a central role in drug metabolism and detoxification, and is consequently vulnerable to injury. The pathogenesis and types of DILI are presented, ranging from hepatic adaptation to hepatocellular injury. Knowledge of the metabolism of anti-TB medications and of the mechanisms of TB DILI is incomplete. Understanding of TB DILI has been hampered by differences in study populations, definitions of hepatotoxicity, and monitoring and reporting practices. Available data regarding the incidence and severity of TB DILI overall, in selected demographic groups, and in those coinfected with HIV or hepatitis B or C virus are presented. Systematic steps for prevention and management of TB DILI are recommended. These include patient and regimen selection to optimize benefits over risks, effective staff and patient education, ready access to care for patients, good communication among providers, and judicious use of clinical and biochemical monitoring. During treatment of latent TB infection (LTBI) alanine aminotransferase (ALT) monitoring is recommended for those who chronically consume alcohol, take concomitant hepatotoxic drugs, have viral hepatitis or other preexisting liver disease or abnormal baseline ALT, have experienced prior isoniazid hepatitis, are pregnant or are within 3 months postpartum. During treatment of TB disease, in addition to these individuals, patients with HIV infection should have ALT monitoring. Some experts recommend biochemical monitoring for those older than 35 years. Treatment should be interrupted and, generally, a modified or alternative regimen used for those with ALT elevation more than three times the upper limit of normal (ULN) in the presence of hepatitis symptoms and/or jaundice, or five times the ULN in the absence of symptoms. Priorities for future studies to develop safer treatments for LTBI and for TB disease are presented.

Key Words: hepatitis • treatment • latent tuberculosis




This article has been cited by other articles:


Home page
ThoraxHome page
N F Walker, M Kliner, D Turner, S Bhagani, I Cropley, S Hopkins, and M Lipman
Hepatotoxicity and antituberculosis therapy: time to revise UK guidance?
Thorax, October 1, 2009; 64(10): 918 - 918.
[Full Text] [PDF]


Home page
Ther Adv Respir DisHome page
A. Semfke, C. Wackernagel, H. Vier, A. Schutz, V. Wiechmann, and A. Gillissen
Histologically proven isoniazid hepatoxicity in complicated tuberculous salpingitis
Therapeutic Advances in Respiratory Disease, August 1, 2009; 3(4): 159 - 162.
[Abstract] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
S. Goutelle, L. Bourguignon, P. H. Maire, M. Van Guilder, J. E. Conte Jr., and R. W. Jelliffe
Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs
Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2974 - 2981.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
R Ramachandran and S Kakar
Histological patterns in drug-induced liver disease
J. Clin. Pathol., June 1, 2009; 62(6): 481 - 492.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
D. P. Holland, G. D. Sanders, C. D. Hamilton, and J. E. Stout
Costs and Cost-effectiveness of Four Treatment Regimens for Latent Tuberculosis Infection
Am. J. Respir. Crit. Care Med., June 1, 2009; 179(11): 1055 - 1060.
[Abstract] [Full Text] [PDF]


Home page
Int J STD AIDSHome page
D J B Marks, K Dheda, R Dawson, G Ainslie, and R F Miller
Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs
Int J STD AIDS, May 1, 2009; 20(5): 339 - 345.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
J. E. Oeltmann, J. S. Kammerer, E. S. Pevzner, and P. K. Moonan
Tuberculosis and Substance Abuse in the United States, 1997-2006
Arch Intern Med, January 26, 2009; 169(2): 189 - 197.
[Abstract] [Full Text] [PDF]


Home page
J Int Assoc Physicians AIDS Care (Chic Ill)Home page
M. Puoti, P. Nasta, F. Gatti, A. Matti, K. Prestini, L. Biasi, and G. Carosi
HIV-Related Liver Disease: ARV Drugs, Coinfection, and Other Risk Factors
J Int Assoc Physicians AIDS Care (Chic Ill), January 1, 2009; 8(1): 30 - 42.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
D. Menzies, R. Long, A. Trajman, M.-J. Dion, J. Yang, H. Al Jahdali, Z. Memish, K. Khan, M. Gardam, V. Hoeppner, et al.
Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection: A Randomized Trial
Ann Intern Med, November 18, 2008; 149(10): 689 - 697.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
Y. Suzuki, S. Miwa, M. Shirai, H. Ohba, M. Murakami, K. Fujita, T. Suda, H. Nakamura, H. Hayakawa, and K. Chida
Drug Lymphocyte Stimulation Test in the Diagnosis of Adverse Reactions to Antituberculosis Drugs
Chest, November 1, 2008; 134(5): 1027 - 1032.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
K. C. Chang, C. C. Leung, W. W. Yew, T. Y. Lau, and C. M. Tam
Hepatotoxicity of Pyrazinamide: Cohort and Case-Control Analyses
Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1391 - 1396.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
M. N. Lobato, J. A. Jereb, and J. R. Starke
Unintended Consequences: Mandatory Tuberculin Skin Testing and Severe Isoniazid Hepatotoxicity
Pediatrics, June 1, 2008; 121(6): e1732 - e1733.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
W. W. Yew and C. C. Leung
Update in Tuberculosis 2007
Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 479 - 485.
[Full Text] [PDF]


Home page
ChestHome page
A. Fernandez-Villar, V. Leiro, M. Botana, B. Sopena, Y. S. Kwon, and W.-J. Koh
Hepatitis C Virus Infection and Isoniazid Hepatotoxicity
Chest, August 1, 2007; 132(2): 736 - 737.
[Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
A. H. Diacon, R. F. Patientia, A. Venter, P. D. van Helden, P. J. Smith, H. McIlleron, J. S. Maritz, and P. R. Donald
Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears
Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2994 - 2996.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
W. W. Yew and C. C. Leung
Antituberculosis Drugs and Hepatotoxicity
Am. J. Respir. Crit. Care Med., April 15, 2007; 175(8): 858 - 858.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. J. Saukkonen, D. L. Cohn, R. M. Jasmer, S. Schenker, J. A. Jereb, C. M. Nolan, C. A. Peloquin, F. M. Gordin, D. Nunes, J. Bernardo, et al.
Antituberculosis Drugs and Hepatotoxicity
Am. J. Respir. Crit. Care Med., April 15, 2007; 175(8): 858a - 859.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2006 American Thoracic Society